Reimbursement dossiers, cost-effectiveness models, and market access strategies carry far more weight when grounded in real clinical data from the Brazilian population — not extrapolations from international studies.
iHealth combines Brazil's largest proprietary longitudinal clinical database with Market Access and HEOR expertise to build the value arguments that CONITEC, ANS, and Latin America's HTAs need to hear.
Most dossiers submitted to CONITEC are built on international epidemiological and economic data — adapted to the Brazilian context through assumptions and extrapolations. The result is predictable: value arguments that don't reflect local clinical reality, economic models with questionable assumptions, and approval rates that could be higher.
iHealth solves this at the source: with real clinical data from Brazilian patients, structured through NLP and clinically validated, we build cost-effectiveness, budget impact, and disease burden analyses that reflect what actually happens in Brazil's healthcare system.
End-to-end development of technical-scientific dossiers for CONITEC submission and ANS reimbursement processes — with clinical and economic evidence based on real data from the Brazilian population. Structure aligned with PDCTS and current methodological guidelines, with a value narrative built from iHealth's proprietary longitudinal data.
Development of pharmacoeconomic models — Markov, decision tree, state transition — parameterized with real clinical data from Brazilian patients. State transitions, utilities, direct costs, and outcomes drawn from iHealth's longitudinal database. Sensitivity analyses and alternative scenarios documented with full methodological traceability.
Estimating the financial impact of incorporating a new technology into Brazil's healthcare system — with real data on prevalence, incidence, current treatment patterns, and care costs. Models calibrated for SUS, private health insurance, or a specific segment. Support for negotiations with payers and health system managers.
Quantifying the clinical, economic, and humanistic impact of a condition on the Brazilian population — prevalence, incidence, direct and indirect costs, quality of life, and quality-adjusted life years (QALYs). Real data, not estimates. Support for strategic product positioning and building the case of need before HTAs.
Competitive positioning analysis, international price benchmarking, and Brazilian market entry strategy — grounded in real epidemiological and economic data. Price scenario modeling with impact on access, volume, and payer financial sustainability. Support for negotiations and building value-based agreements.
Extending Market Access analyses to Latin America's key markets — with methodological adaptation to each regional HTA's requirements. Brazilian data as an anchor, with epidemiological and economic adjustments for Argentina, Colombia, Mexico, and other priority markets. Methodological consistency across submissions and a unified value narrative for the region.
iHealth owns its data infrastructure. We don't broker data from other sources — we generate, structure, and maintain our own longitudinal clinical database, with full control over quality, traceability, and regulatory compliance.
Our NLP engine is not a generic tool adapted to Portuguese. It was built from the ground up for the vocabulary, abbreviations, and narrative structures of Brazilian medical Portuguese — with clinical accuracy validated by specialists.
40+ hospitals across all 5 regions of Brazil — not just São Paulo and Rio. That means real epidemiological representativeness of the Brazilian population, with geographic, demographic, and treatment-pattern diversity.
LGPD-first architecture with anonymization at the source, irreversible hashing, full lineage, and documented legal bases. Outputs ready for regulatory submission to CONITEC, ANVISA, FDA, and EMA.
We have the database. We have the methodology. And we have the hospital partners to support your project — from design to results.
